Richard Collins Biography and Net Worth

Director of DexCom

Mr. Collins has been a self-employed consultant since October 2013. From March 2011 to October 2013 Mr. Collins was the Chief Executive Officer for UnitedHealthcare’s Northeast Region and was at different times the President, Director or Chairman of numerous UnitedHealthcare subsidiaries including Oxford Health Plans, Mid Atlantic Medical Services and UHC Insurance Company of New York. From July 2005 through December 2012 Mr. Collins served as President – Individual Line of Business for UnitedHealthcare and as the Chairman and Chief Executive Officer of Golden Rule Financial Corporation. Prior to 2011, Mr. Collins also held leadership positions in pricing, underwriting and healthcare economics with UnitedHealthcare. During his tenure there, Mr. Collins saw UnitedHealthcare grow from a mid-cap health insurer into one the largest public corporations in America.

Mr. Collins has previously served on the Boards of Fairbanks Hospital in Indianapolis, Indiana, The Indiana Chapter of The Nature Conservancy, UnitedHealthcare Children’s Foundation, and the Council for Affordable Health Insurance.

Mr. Collins brings significant experience in healthcare insurance and administration to our Board.

What is Richard Alexander Collins' net worth?: The estimated net worth of Richard Alexander Collins is at least $192,055.50 as of February 18th, 2020. Mr. Collins owns 2,613 shares of DexCom stock worth more than $192,056 as of November 14th. This net worth estimate does not reflect any other investments that Mr. Collins may own. Learn More about Richard Alexander Collins' net worth.
How do I contact Richard Alexander Collins?: The corporate mailing address for Mr. Collins and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Richard Alexander Collins' contact information.
Has Richard Alexander Collins been buying or selling shares of DexCom?: Richard Alexander Collins has not been actively trading shares of DexCom in the last ninety days. Most recently, Richard Alexander Collins sold 1,500 shares of the business's stock in a transaction on Wednesday, November 3rd. The shares were sold at an average price of $647.05, for a transaction totalling $970,575.00. Learn More on Richard Alexander Collins' trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 29 times. They sold a total of 253,409 shares worth more than $33,229,896.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 9/9/2024.

Richard Alexander Collins Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/3/2021	Sell	1,500	$647.05	$970,575.00
2/18/2020	Sell	4,000	$284.40	$1,137,600.00	2,613

Richard Alexander Collins Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $73.50

$71.75

$73.69

50 Day Range

MA: $69.77

$65.68

$74.85

2 Week Range

Now: $73.50

$62.34

$142.00

Volume

448,942 shs

Average Volume

3,902,760 shs

Market Capitalization

$28.71 billion

P/E Ratio

44.01

Dividend Yield

N/A

Beta

1.17

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.